Patents by Inventor Analia BORTOLOZZI

Analia BORTOLOZZI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
    Patent number: 10125363
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: November 13, 2018
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
    Patent number: 10071163
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: September 11, 2018
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Compositions and methods for selective delivery of oligonucleotide molecules to cell types
    Patent number: 9938525
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalized by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: April 10, 2018
    Assignee: NLIFE THERAPEUTICS, S.L.
    Inventors: Maria del Carmen Carmona Orozco, Andrés Pablo Montefeltro, Gabriel G. Alvarado, Analia Bortolozzi, Raquel Revilla-Sanchez
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
    Publication number: 20170073679
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Applicant: nLife Therapeutics, S.L.
    Inventors: Maria del Carmen CARMONA OROZCO, Andrés MONTEFELTRO, Gabriel ALVARADO URBINA, Analía BORTOLOZZI BIASSONI, Raquel REVILLA-SANCHEZ
  • COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES
    Publication number: 20160235856
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: November 23, 2015
    Publication date: August 18, 2016
    Inventors: Andrés Pablo MONTEFELTRO, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    Publication number: 20160083726
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: July 20, 2015
    Publication date: March 24, 2016
    Inventors: Andrés Pablo MONTEFELTRO, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
    Patent number: 9193969
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: November 24, 2015
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES
    Publication number: 20150315575
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Application
    Filed: October 25, 2013
    Publication date: November 5, 2015
    Inventors: Maria del Carmen CARMONA OROZCO, Andrés Pablo MONTEFELTRO, Gabriel G. ALVARADO, Analia BORTOLOZZI, Raquel REVILLA-SANCHEZ
  • Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
    Patent number: 9084825
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: July 21, 2015
    Assignee: nLife Therapeutics, S.L.
    Inventors: Andrés Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover, Maria del Carmen Carmona Orozco
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
    Publication number: 20140315795
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Application
    Filed: October 25, 2013
    Publication date: October 23, 2014
    Inventors: Maria del Carmen CARMONA OROZCO, Andrés Montefeltro, Gabriel Alvarado Urbina, Analía Bortolozzi Biassoni, Raquel Revilla-Sanchez
  • Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    Publication number: 20140120158
    Abstract: The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is ?-synuclein or the mRNA encoding ?-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 1, 2014
    Inventors: Andrés Pablo MONTEFELTRO, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Pérez, Miquel Vila Bover
  • Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
    Publication number: 20120322991
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
    Type: Application
    Filed: April 19, 2011
    Publication date: December 20, 2012
    Applicant: NLIFE THERAPEUTICS, S.L.
    Inventors: Andres Pablo Montefeltro, Gabriel Alvarado Urbina, Analia Bortolozzi Biassoni, Francesc Artigas Perez, Miquel Vila Bover